Wegovy Week by Week Results: What Actually Happens and When

The biggest myth: 'I should be losing weight from week one'

The misconception our prescribers hear most weeks is that Wegovy should be producing visible results almost immediately. It won't, and that's by design, not a sign anything has gone wrong. Treatment opens at 0.25mg, a dose too low to drive meaningful appetite suppression. Its job is to let your body adjust before the dose climbs. Nausea, indigestion and fatigue are common early on, and those symptoms tend to peak precisely when the medicine hasn't yet reached a therapeutic level. Expecting weight loss at this stage sets people up for unnecessary worry.

The dose typically increases every four weeks or so, guided by your prescriber, moving through 0.5mg, 1.0mg, 1.7mg and on to the 2.4mg maintenance dose. Each step up carries a fresh adjustment period. The NHS patient information for semaglutide explains this titration clearly: the escalation schedule exists to reduce side effects, not delay results. Real appetite change (eating less without much effort, feeling full earlier) tends to become noticeable somewhere around weeks four to eight for most people, once the dose has started to climb.

Weight loss that reads on the scale usually follows a few weeks behind that appetite shift. Keep a weekly record, but look at the four-week trend rather than day-to-day movement. That's the figure that tells you something useful.

Weeks one to twelve: what the data actually shows

In the STEP 1 trial, participants lost roughly 6% of body weight by around week 12. That's an average across thousands of adults, some lost more, some less. The number sounds modest; across an actual body it often isn't. A 90kg person losing 6% has lost more than five kilograms. The pace tends to feel slow in these early weeks because it is slow, and because appetite suppression is building rather than fully established.

By around week 20, average losses in the trial were approaching 10%. The trajectory is roughly S-shaped: slow start, steeper middle, then a gradual flattening as body weight stabilises at a new set point. If you're curious about what six weeks on Wegovy tends to look like in practice, that page walks through the picture in more detail.

The first week carries its own specific experience. Appetite can dip slightly, some people notice this, others don't at 0.25mg. You can read about Wegovy's first-week effects in a dedicated page. The second week often brings more noticeable GI adjustment as the medicine settles; week two on Wegovy covers that transition specifically.

The middle months: where most of the loss happens

Weeks twelve to forty represent the steepest part of the curve for the majority of people. Dose has usually reached 2.4mg by around month four, and appetite suppression at maintenance dose is substantially stronger than at the starter level. Calorie intake drops, often without conscious restriction, because hunger signals genuinely change. That's the mechanism, semaglutide acts on GLP-1 receptors involved in appetite regulation and slows how quickly the stomach empties.

Plateaus will appear. A stretch of two or three weeks with no movement on the scale is not unusual and doesn't mean treatment has stopped working. It's worth reading the broader picture of how semaglutide results build week by week for context on this. The correct response to a plateau is patience and a review with your prescriber, not skipping a dose or adjusting timing independently. For a broader sense of the timeline, how long Wegovy takes to work addresses the full arc.

Muscle loss during significant calorie reduction is a real consideration. Protein intake and some resistance activity help preserve lean mass. Your prescriber or a dietitian can advise on this specifically; it's not something to address by slowing the dose escalation.

Beyond week 68: maintenance, the 7.2mg dose, and what happens if you stop

The STEP 1 trial ran to 68 weeks, averaging roughly 15% weight loss at its close. That figure is real, and for a medicine taken by injection once a week, it represents a meaningful shift in how weight management has been possible for many adults. The NICE recommendation for semaglutide (Wegovy) (detailed in NICE technology appraisal TA875) covers use for a maximum of two years within a specialist service. Private treatment through a regulated pharmacy follows the licensed indication; your prescriber reviews the position at each repeat.

The MHRA's approval of a 7.2mg single-dose pen in April 2026 added a higher maintenance option. Trials at that dose showed around 20.7% average weight loss over 72 weeks. Availability at this dose is confirmed through clinical review, not assumed. If you're weighing up what Wegovy costs across the full treatment period, that page sets out the pricing context honestly.

Stopping treatment without a plan tends to reverse a meaningful portion of the loss over the following months, this is a known pharmacological effect, not a failure of willpower. The medicine suppresses the appetite signals; when it's withdrawn, those signals return. Maintenance strategies, including lifestyle anchoring during treatment, are worth discussing with a prescriber well before stopping rather than after. If you'd like to explore treatment options more broadly, our overview of weight-loss treatments covers what's currently licensed in the UK.